The Phase III trial met the primary and secondary endpoints of reducing tics in children and adult patients with Tourette ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback